Targegen, Inc.
Records under this name other than patents Targegen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,825,246 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,133,900 | Use of Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · High confidence | In force | High confidence | |
| US 8,138,199 | Use of Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · High confidence | In force | High confidence | |
| US 7,528,143 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,391,094 | Compositions and Methods for Treating Myelofibrosis Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,604,042 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held Term ended Term ended Oct 26, 2026 · High confidence | Term ended | Term ended Oct 26, 2026 | High confidence |
| US 7,652,051 | Heterocyclic compounds and methods of use Term ended Term ended Aug 6, 2026 · From the USPTO record | Term ended | Term ended Aug 6, 2026 | From the USPTO record |
| US 7,456,176 | Benzotriazine inhibitors of kinases Term ended Term ended Jul 3, 2026 · From the USPTO record | Term ended | Term ended Jul 3, 2026 | From the USPTO record |
| US 8,481,536 | Benzotriazine inhibitors of kinases Term ended Term ended Apr 7, 2025 · From the USPTO record | Term ended | Term ended Apr 7, 2025 | From the USPTO record |
| US 8,372,971 | Heterocyclic compounds and methods of use Lapsed on the fee record Ended Feb 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2025 | From the USPTO record |